Plain-English translation of NCT04285567 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Leukemia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial examined whether and —two newer medications used together—could work better and be safer than standard chemotherapy treatments for people with newly diagnosed chronic lymphocytic leukemia (a blood cancer affecting white blood cells). About 166 people with this condition were randomly assigned to receive either the newer medication combination or one of two standard chemotherapy regimens, and researchers compared how well each treatment worked and what side effects occurred.
Standard chemotherapy for this blood cancer has been used for many years, but doctors wanted to know whether this newer medication combination might be more effective or cause fewer side effects for patients in good overall health with newly diagnosed disease.
Participants were randomly assigned to one of two groups: one group received 12 cycles (each lasting 28 days) of the newer medication combination, which included daily oral medication and periodic intravenous infusions; the other group received 6 cycles of standard chemotherapy given by intravenous infusion. Throughout the trial, participants attended regular clinic visits for treatment, blood tests, and monitoring of their health and any side effects.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
United States
Australia